Emily Bodnar
Stock Analyst at H.C. Wainwright
(3.73)
# 2,023
Out of 4,556 analysts
652
Total ratings
36.1%
Success rate
4.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Maintained: Buy | $54 → $52 | $36.05 | +44.24% | 23 | Jul 21, 2026 | |
| RCUS Arcus Biosciences | Rated: Buy | $32 → $45 | $29.97 | +50.15% | 19 | Jul 20, 2026 | |
| NXTC NextCure | Maintained: Buy | $20 | $4.40 | +354.55% | 15 | Jul 15, 2026 | |
| AGEN Agenus | Maintained: Buy | $23 → $30 | $5.53 | +442.50% | 39 | Jul 13, 2026 | |
| TGTX TG Therapeutics | Maintained: Buy | $70 → $77 | $52.68 | +46.17% | 12 | Jul 13, 2026 | |
| NVCR NovoCure | Maintained: Buy | $46 | $15.57 | +195.44% | 44 | Jul 13, 2026 | |
| AUTL Autolus Therapeutics | Maintained: Buy | $10 | $1.44 | +594.44% | 5 | Jul 13, 2026 | |
| COAG Hemab Therapeutics Holdings | Maintained: Buy | $40 → $52 | $49.23 | +5.63% | 3 | Jul 13, 2026 | |
| TRAX First Tracks Biotherapeutics | Reiterated: Buy | $30 → $44 | $38.17 | +15.27% | 3 | Jul 10, 2026 | |
| ATOS Atossa Therapeutics | Rated: Hold | n/a | $2.43 | - | 27 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $3.58 | +179.33% | 11 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.6134 | +715.13% | 38 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $10.02 | +249.30% | 9 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $11.49 | +230.72% | 46 | Jun 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $31.67 | +42.09% | 10 | May 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $1.33 | +2,155.64% | 19 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $0.4405 | +2,624.18% | 5 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $10.24 | +241.80% | 26 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $1.68 | +1,030.95% | 23 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $2.41 | +563.90% | 30 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $3.12 | +124.36% | 26 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $31 | $2.96 | +947.30% | 15 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.41 | - | 13 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $1.59 | +1,472.33% | 26 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55 → $66 | $52.61 | +25.45% | 20 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $20 | $0.7448 | +2,585.28% | 21 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $5.35 | +236.45% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.001 | - | 24 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56.30 | $5.16 | +991.05% | 34 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $3.52 | +4,445.45% | 32 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.02 | n/a | 22 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $2.20 | n/a | 5 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.84 | n/a | 6 | May 22, 2024 |
Agios Pharmaceuticals
Jul 21, 2026
Maintained: Buy
Price Target: $54 → $52
Current: $36.05
Upside: +44.24%
Arcus Biosciences
Jul 20, 2026
Rated: Buy
Price Target: $32 → $45
Current: $29.97
Upside: +50.15%
NextCure
Jul 15, 2026
Maintained: Buy
Price Target: $20
Current: $4.40
Upside: +354.55%
Agenus
Jul 13, 2026
Maintained: Buy
Price Target: $23 → $30
Current: $5.53
Upside: +442.50%
TG Therapeutics
Jul 13, 2026
Maintained: Buy
Price Target: $70 → $77
Current: $52.68
Upside: +46.17%
NovoCure
Jul 13, 2026
Maintained: Buy
Price Target: $46
Current: $15.57
Upside: +195.44%
Autolus Therapeutics
Jul 13, 2026
Maintained: Buy
Price Target: $10
Current: $1.44
Upside: +594.44%
Hemab Therapeutics Holdings
Jul 13, 2026
Maintained: Buy
Price Target: $40 → $52
Current: $49.23
Upside: +5.63%
First Tracks Biotherapeutics
Jul 10, 2026
Reiterated: Buy
Price Target: $30 → $44
Current: $38.17
Upside: +15.27%
Atossa Therapeutics
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $2.43
Upside: -
Jun 15, 2026
Reiterated: Buy
Price Target: $10
Current: $3.58
Upside: +179.33%
Jun 15, 2026
Maintained: Buy
Price Target: $5
Current: $0.6134
Upside: +715.13%
Jun 8, 2026
Maintained: Buy
Price Target: $35
Current: $10.02
Upside: +249.30%
Jun 3, 2026
Reiterated: Buy
Price Target: $38
Current: $11.49
Upside: +230.72%
May 26, 2026
Maintained: Buy
Price Target: $45
Current: $31.67
Upside: +42.09%
May 18, 2026
Reiterated: Buy
Price Target: $30
Current: $1.33
Upside: +2,155.64%
May 15, 2026
Maintained: Buy
Price Target: $12
Current: $0.4405
Upside: +2,624.18%
May 15, 2026
Maintained: Buy
Price Target: $35
Current: $10.24
Upside: +241.80%
May 14, 2026
Reiterated: Buy
Price Target: $19
Current: $1.68
Upside: +1,030.95%
May 13, 2026
Maintained: Buy
Price Target: $16
Current: $2.41
Upside: +563.90%
May 12, 2026
Reiterated: Buy
Price Target: $7
Current: $3.12
Upside: +124.36%
May 8, 2026
Maintained: Buy
Price Target: $31
Current: $2.96
Upside: +947.30%
May 6, 2026
Maintained: Hold
Price Target: n/a
Current: $1.41
Upside: -
Apr 2, 2026
Maintained: Buy
Price Target: $25
Current: $1.59
Upside: +1,472.33%
Mar 30, 2026
Maintained: Buy
Price Target: $55 → $66
Current: $52.61
Upside: +25.45%
Mar 30, 2026
Rated: Buy
Price Target: $20
Current: $0.7448
Upside: +2,585.28%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $5.35
Upside: +236.45%
Nov 17, 2025
Maintained: Hold
Price Target: n/a
Current: $0.001
Upside: -
Oct 13, 2025
Maintained: Buy
Price Target: $56.30
Current: $5.16
Upside: +991.05%
Sep 26, 2025
Maintained: Buy
Price Target: $160
Current: $3.52
Upside: +4,445.45%
Apr 29, 2025
Rated: Hold
Price Target: n/a
Current: $8.02
Upside: n/a
Mar 31, 2025
Maintained: Buy
Price Target: $8
Current: $2.20
Upside: n/a
May 22, 2024
Rated: Hold
Price Target: n/a
Current: $2.84
Upside: n/a